“Sofosbuvir plus Daclatasvir without Ribavirin for the Treatment of Chronic Hepatitis C in Patients with Decompensated Liver Disease: Response of sofosbuvir plus daclatasvir in decompensated cirrhosis”, J Fatima Jinnah Med Univ, vol. 14, no. 1, pp. 41–44, Jul. 2020, doi: 10.37018/WOXS1774.